Frank Pallone

Mr. PALLONE

Mr. PALLONE. Madam Speaker, I reserve the balance of my time.

Mr. PALLONE. Madam Speaker, I reserve the balance of my time.

Mr. PALLONE. Madam Speaker, I have no further speakers, and I reserve the balance of my time.

Mr. PALLONE. Madam Speaker, I would urge support for this bipartisan bill, and I yield back the balance of my time.

Mr. PALLONE

Mr. PALLONE. Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days in which to revise and extend their remarks and include extraneous material on H.R. 172.

Mr. PALLONE. Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 172) to reauthorize the United States Anti-Doping Agency, and for other purposes.

Mr. PALLONE. Mr. Speaker, I yield myself such time as I may consume. I rise today in support of H.R. 172, the United States Anti-Doping Agency Reauthorization Act of 2021. For two decades, Mr. Speaker, the United States Anti-Doping Agency, or USADA, has worked to ensure integrity in our American Olympic and Paralympic sporting activities through the promotion and support of drug-free competition. Recommended by an Olympic committee task force, this independent organization was established to manage a comprehensive anti-doping program in the United States. And since its authorization in 2000, USADA has helped to advance clean sports through scientific research, anti-doping education, and outreach programs. To ensure USADA can continue this good work, H.R. 172 would extend and increase the authorization level through fiscal year 2030. Further, this bill would empower USADA to encourage a positive sporting environment for young athletes by providing educational materials on sportsmanship, character building, and healthy performance. The bill also improves anti-doping efforts in the U.S. by encouraging Federal agencies to coordinate and share information with USADA to prevent the use of performance-enhancing drugs and methods. Taken together, these actions will make positive improvements to the good work that USADA is already doing and provide critical support as we lead up to the 2028 Summer Olympic and Paralympic Games in Los Angeles. I want to thank my colleagues, Representatives Mike Thompson, Diana DeGette, and Bill Johnson for leading this important bipartisan legislation. I would also like to thank Ranking Member Rodgers and all the members and staff of our committee for their efforts to move this legislation forward in a bipartisan manner. Mr. Speaker, I urge my colleagues to support this legislation, and I reserve the balance of my time.

Mr. PALLONE. Mr. Speaker, I yield 3 minutes to the gentleman from California (Mr. Thompson) who is the lead sponsor of the legislation.

Mr. PALLONE. Mr. Speaker, I have no additional speakers. I urge support for the legislation, and I yield back the balance of my time.

Mr. PALLONE

Mr. PALLONE. Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 189) to amend the Public Health Service Act to provide that the authority of the Director of the National Institute on Minority Health and Health Disparities to make certain research endowments applies with respect to both current and former centers of excellence, and for other purposes.

Mr. PALLONE. Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days in which to revise and extend their remarks and include extraneous material on H.R. 189.

Mr. PALLONE

Mr. PALLONE. Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 941) to reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

Mr. PALLONE. Mr. Speaker, I also urge support for the bill, and I yield back the balance of my time.

Mr. PALLONE

Mr. PALLONE. Mr. Speaker, I move to suspend the rules and pass the bill (S. 164) to educate health care providers and the public on biosimilar biological products, and for other purposes.

Mr. PALLONE. Mr. Speaker, I also urge support for this bill, and I yield back the balance of my time.

Mr. PALLONE

Mr. PALLONE. Mr. Speaker, I move to suspend the rules and pass the bill (S. 415) to amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity.

Mr. PALLONE. Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days in which to revise and extend their remarks and include extraneous material on S. 415.

Mr. PALLONE

Mr. PALLONE. Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 1460) to encourage States to require the installation of residential carbon monoxide detectors in homes, and for other purposes.

Mr. PALLONE

Mr. PALLONE. Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 446) to require the Federal Trade Commission to submit a report to Congress on scams targeting seniors, and for other purposes.

Mr. PALLONE. Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days in which to revise and extend their remarks and include extraneous material on H.R. 446.

Mr. PALLONE

Mr. PALLONE. Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 1762) to direct the Federal Trade Commission to submit to Congress a report on unfair or deceptive acts or practices targeted at Indian Tribes or members of Indian Tribes, and for other purposes.

Mr. PALLONE

Mr. PALLONE. Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 1766) to enhance cooperation between the Federal Trade Commission and State Attorneys General to combat unfair and deceptive practices, and for other purposes.

Mr. PALLONE

Mr. PALLONE. Madam Speaker, I ask unanimous consent that all Members may have 5 legislative days in which to revise and extend their remarks and include extraneous material on H.R. 1002.

Mr. PALLONE

Mr. PALLONE. Madam Speaker, I also urge support for the bill, and I yield back the balance of my time.

Mr. PALLONE

Mr. PALLONE. Mr. Speaker, I move to suspend the rules and pass the bill (S. 578) to improve the health and safety of Americans living with food allergies and related disorders, including potentially life- threatening anaphylaxis, food protein-induced enterocolitis syndrome, and eosinophilic gastrointestinal diseases, and for other purposes.